Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.20 · Revenue $15.19M · 6 analysts
Est. EPS $-0.22 · Revenue $20.82M · 6 analysts
Est. EPS $-0.83 · Revenue $61.51M · 6 analysts
Est. EPS $-0.35 · Revenue $26.46M · 2 analysts
EPS $-0.22 · Revenue $5.22M
EPS $-0.18 · Revenue $5.80M
EPS $-0.68 · Revenue $72.95M
EPS $0.01 · Revenue $35.17M
EPS $-0.24 · Revenue $16.73M
EPS $-0.18 · Revenue $10.65M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $72.9M | +75.8% | -9.9% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-67.6M | -83.9% | -22.2% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +86.6% | +11.2% | -27.3% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -45.3% | +68.4% | -4.3% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -92.7% | -4.6% | -35.7% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-42.5M | -317.7% | +8.1% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -58.3% | -223.9% | -2.0% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 158.0% | +126.3% | +13.6% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.62x | -6.1% | -10.1% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $324.7M | -15.3% | -7.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.68 vs -0.76 | +10.2% | -0.22 vs -0.26 | +16.3% |
| Revenue Surprise | $72.9M vs $77.3M | -5.7% | $5.2M vs $11.0M | -52.7% |
Operator: Hello, and welcome, everyone, to today's Cellectis' Full Year 2025 Earnings Conference Call. Please note this call is being recorded . It is now my pleasure to turn the meeting over to Arthur Stril, Chief Financial Officer and Chief Business Officer. Please go ahead. Arthur Stril: Good morning, and welcome, everyone, to Cellectis Fourth Quarter and Full Year 2025 Business Update and Financial Results Conference Call. Joining me on the call today are Dr. Andre Choulika, our Chief Executive Officer; and Dr. Adrian Kilcoyne, our Chief Medical Officer. Yesterday evening, Cellectis issued a 20-F and press release reporting our financial statements for the 12-month period ended December 31, 2025, and a business update. The report and press release are available on our website at cellectis.com. As a reminder, we will make statements regarding Cellectis' financial outlook, including the sufficiency of cash to fund operations in addition to its manufacturing, regulatory and product development status as well as product development status of its license partners. These forward statements, which are based on our management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20-F filed with the Securities and Exchange Commission, SEC, and the financial report, including the management report for the year ended on December 31, 2025, and subsequent filings Cellectis makes with the SEC from time to time. I would now like to turn the call over to Andre. André Choulika: Thank you, Arthur. Good morning, and thank you, everyone, for joining us today. Cellectis was founded with the conviction that gene editing could fundamentally transform how we treat patients in the 21st century. That foundation and ID, we pioneered the allogeneic CAR T approach ready on day 1, built for all patients regardless of their condition. Today, I'm proud to say that Cellectis is the one of the only company running a pivotal Phase II allogeneic CAR T trial, specifically in B-cell acute lymphoblastic leukemia. The past several years have been among the most challenging in recent memory of biotechnology companies. Many programs were shelved and many companies were forced to retreat. While others were stepped back, Cellectis stepped forward. We held the line. We manage our cash with rigor. We invested where it matters, and we kept our team focused entirely on one thing, delivering clinical results for patients who are running out of time with no therapeutic solution. In 2025, that discipline paid off. In October, at our R&D Day, we presented the full Phase I data set for lasme-cel, our allogeneic CAR T candidate targeting CD22 in relapsed or refractory B-cell acute lymphoblastic leukemia. …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Andre Choulika | Co-Founder, Chief Executive Officer & Director | USD 982,873 | — | 1965 | Active |
David J. Sourdive | Co-Founder, Deputy Chief Executive Officer, Executive Vice President of CMC & Manufacturing and Director | USD 636,274 | — | 1967 | Active |
Marie-Bleuenn Terrier | General Counsel & Secretary of the Board of Directors | — | Female | 1982 | Active |
Pascalyne Wilson | Director of Communications | — | — | — | Active |
Stephan Reynier | Chief Regulatory & Pharmaceutical Compliance Officer | — | Male | 1969 | Active |
Kyung Nam-Wortman | Executive Vice President & Chief Human Resources Officer | — | Female | 1970 | Active |
Jean Charles Epinat | Chief Technological Officer | — | Male | — | Active |
Valerie Cros | Principal Financial Officer & Principal Accounting Officer | — | — | — | Active |
Philippe Duchateau | Chief Scientific Officer | — | — | 1963 | Active |
Arthur Stril | Chief Financial Officer & Chief Business Officer | — | Male | 1989 | Active |
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026 after the close of the US market.
EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced two additions to its executive leadership team: Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer.
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, presents final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preliminary data from the NATHALI-01 study evaluating eti-cel, a dual CD20 and CD22 directed CAR-T in relapsed/refractory B-cell non Hodgkin lymphoma (r/r B-NHL), at the European Hematology Association (EHA) 2026 Annual Congress.
